GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly...
Ribo Life Science Raises USD 40M in Series E1 Round for siRNA Drug Development
China-based Suzhou Ribo Life Science Co., Ltd reportedly raised USD 40 million in a Series...
BridGene Biosciences Completes USD 38.5M Series B Round with China Funds
U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5...
Basecare Medical Sells 35% Stake in Cellpro Biotech for USD 9.5M
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based IVF specialist, will sell a 35%...
Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical...
Pica Partners with BrainCo to Launch ADHD Product in China
Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with...
NHC Designates National Mental Illness Medical Centers in Beijing and Shanghai
The National Healthcare Commission (NHC) announced the establishment of national mental illness medical centers, designating...
Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors
China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...
Dongcheng Pharmaceutical Gets NMPA Green Light for PSMA PET Imaging Drug
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced it has received approval from...
CanSino Biologics Launches Menhycia Meningococcal Vaccine in Six Provinces
China-based CanSino Biologics (HKG: 6185) announced the launch of its ACYW135 Meningococcal Conjugate Vaccine (CRM197)...
Mabwell Bioscience Gets FDA Approval for Nectin-4 ADC 9MW2821 in Solid Tumors
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received approval from the...
LaNova Medicines Gets FDA Green Light for LM-305 Myeloma Study
Shanghai-based cancer therapy developer LaNova Medicines Ltd announced it has received approval from the U.S....
Sanofi’s Q2 Earnings Show 8.1% Global Sales Growth, Led by Dupixent and China Expansion
France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3...
CSPC Pharmaceutical’s Albumin-Bound Docetaxel Receives Orphan Drug Designation for Gastric Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received an orphan drug...
Hybio Pharmaceutical’s Liraglutide Filing Accepted by NMPA, Becomes Domestic Leader in GLP-1 Analog
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its market filing for liraglutide, a...
Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors
Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...
Kira Pharmaceuticals’ KP104 Receives Orphan Drug Designation for PNH Treatment
Sino-US biotech Kira Pharmaceuticals announced that it has received an Orphan Drug Designation (ODD) from...
Shenzhen Unveils Measures to Boost Biomedical and Medical Device Industries
Shenzhen’s municipal Development and Reform Commission has released a series of measures to promote the...
Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth
US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD...
Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment
Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib)...